Determination of the minimum effective concentration (MEC90) of dexmedetomidine for prolonged analgesia in patients undergoing interscalene brachial plexus block

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002933

Enrollment

Registered

2018-06-19

Start date

2018-06-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : With the initial concentration of dexmedetomidine determined, the concentration of the drug in the next patient is determined by the success or failure of the previous study participants. The i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult (>20 years old or =20, <70 years old) patients with written informed consent American society of anesthesiologist physical status I-III: Previous healthy (I), controlled systemic disease (II), uncontrolled systemic disease (III)

Exclusion criteria

Exclusion criteria: American society of anesthesiologist physical status higher than IV Child or old age Sensory or motor deficit Allergy to local anesthetic Allergy to dexmedetomidine Local infection at the site of interscalene brachial plexus block or systemic infection Hepatic, cardiac, or renal disease Coagulopathy (Prolonged INR>1.5) Pregnancy Patient refusal

Design outcomes

Primary

Measure	Time frame
Time to first pain at surgical site	—

Secondary

Measure	Time frame
The incidence of hypotension;The incidence of bradycardia;cumulative opioid consumption at 24 hours postoperatively;patient satisfaction with pain relief;Quality of sleep at the fisrt postoperative night;pain score;block-related complications	—

Countries

Korea, Republic of

Contacts

Public ContactRyung Kang

Samsung Medical Center

Outcome results